Vecuronium bromide - Generic Drug Details

What are the generic drug sources for vecuronium bromide and what is the scope of freedom to operate?

Vecuronium bromide is the generic ingredient in two branded drugs marketed by Organon Usa Inc, Eugia Pharma, Gland, Hikma, Hospira, Meitheal, Mylan Labs Ltd, Sagent Pharms Inc, Sun Pharm, and Watson Labs, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for vecuronium bromide. Ten suppliers are listed for this compound.

Summary for vecuronium bromide

US Patents:	0
Tradenames:	2
Applicants:	10
NDAs:	13
Drug Master File Entries:	5
Finished Product Suppliers / Packagers:	10
Raw Ingredient (Bulk) Api Vendors:	84
Clinical Trials:	12
Patent Applications:	2,651
What excipients (inactive ingredients) are in vecuronium bromide?	vecuronium bromide excipients list
DailyMed Link:	vecuronium bromide at DailyMed

Recent Clinical Trials for vecuronium bromide

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Second Affiliated Hospital of Harbin Medical University	Phase 4
Ningbo No. 1 Hospital	Phase 4
Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University	Phase 4

See all vecuronium bromide clinical trials

Pharmacology for vecuronium bromide

Drug Class	Nondepolarizing Neuromuscular Blocker
Physiological Effect	Neuromuscular Nondepolarizing Blockade

Medical Subject Heading (MeSH) Categories for vecuronium bromide

Neuromuscular Nondepolarizing Agents

Nicotinic Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for vecuronium bromide

M03AC	Other quaternary ammonium compounds
M03A	MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
M03	MUSCLE RELAXANTS
M	Musculo-skeletal system

US Patents and Regulatory Information for vecuronium bromide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	VECURONIUM BROMIDE	vecuronium bromide	INJECTABLE;INJECTION	075164-002	Oct 21, 1999	AP	RX	No	No
Hospira	VECURONIUM BROMIDE	vecuronium bromide	INJECTABLE;INJECTION	075164-001	Oct 21, 1999	AP	RX	No	No
Eugia Pharma	VECURONIUM BROMIDE	vecuronium bromide	INJECTABLE;INJECTION	206670-002	Dec 20, 2018	AP	RX	No	No
Sagent Pharms Inc	VECURONIUM BROMIDE	vecuronium bromide	INJECTABLE;INJECTION	078274-002	Dec 29, 2008	AP	RX	No	No
Hospira	VECURONIUM BROMIDE	vecuronium bromide	INJECTABLE;INJECTION	075558-001	Sep 11, 2001		DISCN	No	No
Mylan Labs Ltd	VECURONIUM BROMIDE	vecuronium bromide	INJECTABLE;INJECTION	090243-001	May 11, 2010	AP	RX	No	No

Expired US Patents for vecuronium bromide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-003	Jan 3, 1992
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-003	Jan 3, 1992
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984

Vecuronium bromide Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Vecuronium Bromide

Introduction to Vecuronium Bromide

Vecuronium bromide is an FDA-approved, peripherally acting, monoquarternary, steroidal, non-depolarizing neuromuscular blocker. It is widely used during general anesthesia to facilitate endotracheal intubation and surgical relaxation, and in intensive care settings to achieve paralysis for mechanical ventilation in appropriately sedated patients[2].

Market Size and Growth

The global vecuronium bromide market has been experiencing significant growth. As of 2023, the market size was valued at several million dollars, and it is anticipated to grow at a compound annual growth rate (CAGR) from 2024 to 2031. This growth is driven by increasing demand in various medical sectors, particularly in surgery and intensive care[1][4].

Market Segmentation

By Type

The vecuronium bromide market is segmented based on the purity of the compound, primarily into two categories: ≥ 98% and < 98%. The ≥ 98% segment accounted for a noticeable share of the global market in 2023 and is projected to experience significant growth in the near future[1][4].

By Application

The primary applications of vecuronium bromide include surgery and tracheal intubation. The medicine segment, which encompasses these applications, is expected to expand at a significant CAGR throughout the forecast period[4].

Key Drivers

Increasing Demand in Medical Sectors

The demand for vecuronium bromide is increasing due to its critical role in surgical procedures and intensive care. The need for effective neuromuscular blockers to facilitate endotracheal intubation and surgical relaxation drives the market growth[2].

Technological Advancements

Technological advancements in the production of high-quality chemicals are a significant driver. Manufacturers are focusing on improving the purity and efficacy of vecuronium bromide, which enhances its market appeal[1].

Regulatory Environment

Environmental and safety regulations play a crucial role in shaping the chemical industry. Compliance with these regulations ensures the safe production and distribution of vecuronium bromide, supporting market growth[1].

Restraints and Challenges

Raw Material Availability

The availability of raw materials can be a restraint. Fluctuations in the supply of necessary chemicals can impact production and pricing[1].

Economic Conditions

Economic conditions, including inflation and global economic downturns, can affect the market. These factors can influence the purchasing power of healthcare institutions and the overall demand for vecuronium bromide[1].

Regulatory Changes

Changes in regulatory policies can also pose challenges. Stricter regulations or changes in approval processes can impact the production and distribution of vecuronium bromide[1].

Opportunities

Expanding Healthcare Infrastructure

The expansion of healthcare infrastructure, particularly in emerging markets, presents significant opportunities for growth. Increasing access to healthcare services in these regions drives the demand for essential medical drugs like vecuronium bromide[1].

Research and Development

Continuous research and development in the field of neuromuscular blockers offer opportunities for innovation. Improving the efficacy and safety of vecuronium bromide can further enhance its market position[2].

Competitive Landscape

The vecuronium bromide market is highly competitive, with several key players dominating the landscape. These include:

• Jiupai Group
• Credit Chemwerth Pharmaceutical
• Beijing Xinze Medical Technology
• Xianju Pharma
• Jiangsu Nhwa Pharmaceutical
• Curia
• Teva API[1][4].

These companies are focusing on strategy building, product portfolio expansion, and technological advancements to strengthen their market positions.

Regional Analysis

The market is analyzed across various regions, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa. Each region has its unique market dynamics, driven by local healthcare needs, regulatory environments, and economic conditions.

• North America: This region is characterized by advanced healthcare infrastructure and stringent regulatory standards, which influence the market dynamics.
• Europe: Similar to North America, Europe has a well-developed healthcare system and strict regulations.
• Asia-Pacific: This region is experiencing rapid growth due to expanding healthcare infrastructure and increasing demand for medical services.
• South America and Middle East & Africa: These regions offer growth opportunities due to improving healthcare access and infrastructure[1].

Financial Trajectory

Revenue and Volume Forecast

The global vecuronium bromide market is expected to witness significant revenue growth from 2024 to 2031. The market value is forecasted to increase substantially, driven by the increasing demand and expanding applications of vecuronium bromide[1][4].

Company Share and Competitive Landscape

The competitive landscape is expected to remain dynamic, with key players competing to increase their market share. Companies are investing in research and development, and strategic partnerships to enhance their product portfolios and market presence[1][4].

Growth Factors and Trends

The market is influenced by several growth factors, including technological advancements, increasing healthcare expenditure, and the expanding need for neuromuscular blockers in surgical and intensive care settings. Trends such as the adoption of high-quality and environmentally friendly products are also driving the market forward[1].

Technological Trends

Technological advancements in the production of vecuronium bromide are crucial for market growth. Improvements in manufacturing processes and the development of higher purity products are key trends. For instance, the focus on producing vecuronium bromide with purity levels above 98% is a significant technological trend[1][4].

Environmental and Safety Regulations

Environmental and safety regulations are vital in shaping the vecuronium bromide market. Compliance with these regulations ensures the safe production, distribution, and use of the drug. Manufacturers must adhere to strict guidelines to maintain market approval and consumer trust[1].

COVID-19 Impact

The COVID-19 pandemic had a mixed impact on the vecuronium bromide market. While the pandemic disrupted supply chains and affected production, the increased need for critical care services also boosted the demand for neuromuscular blockers like vecuronium bromide. The market has been recovering and is expected to continue growing as healthcare systems normalize[1].

Key Takeaways

• Market Growth: The global vecuronium bromide market is expected to grow significantly from 2024 to 2031, driven by increasing demand in medical sectors.
• Segmentation: The market is segmented by type (≥ 98% and < 98%) and application (surgery and tracheal intubation).
• Key Drivers: Increasing demand, technological advancements, and regulatory compliance are key drivers.
• Competitive Landscape: The market is competitive with several key players focusing on strategy building and product portfolio expansion.
• Regional Analysis: The market dynamics vary across regions, with Asia-Pacific showing rapid growth.

FAQs

What is vecuronium bromide used for?

Vecuronium bromide is used as a neuromuscular blocker during general anesthesia to facilitate endotracheal intubation and surgical relaxation, and in intensive care settings to achieve paralysis for mechanical ventilation[2].

Who are the main players in the vecuronium bromide market?

The main players include Jiupai Group, Credit Chemwerth Pharmaceutical, Beijing Xinze Medical Technology, Xianju Pharma, Jiangsu Nhwa Pharmaceutical, Curia, and Teva API[1][4].

What are the key segments of the vecuronium bromide market?

The market is segmented by type (≥ 98% and < 98%) and application (surgery and tracheal intubation)[1][4].

How has the COVID-19 pandemic affected the vecuronium bromide market?

The pandemic had a mixed impact, disrupting supply chains but also increasing demand for critical care services, which boosted the need for vecuronium bromide[1].

What are the key growth drivers for the vecuronium bromide market?

Key drivers include increasing demand in medical sectors, technological advancements, and compliance with environmental and safety regulations[1].

Sources

1. Global Vecuronium Bromide Market Report 2024 Edition - Cognitivemarketresearch.com
2. Vecuronium - StatPearls - NCBI Bookshelf - Ncbi.nlm.nih.gov
3. Antimicrobial Drugs Market Returns Analysis - Aspe.hhs.gov
4. Global Vecuronium Bromide Market Research Report 2024 - Valuates.com